Equities research analysts predict that Cerecor Inc (NASDAQ:CERC) will post sales of $5.45 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Cerecor’s earnings. The lowest sales estimate is $5.30 million and the highest is $5.60 million. The firm is expected to report its next quarterly earnings report on Thursday, February 13th.
On average, analysts expect that Cerecor will report full year sales of $20.20 million for the current fiscal year. For the next year, analysts forecast that the business will report sales of $22.80 million, with estimates ranging from $22.60 million to $23.00 million. Zacks’ sales averages are an average based on a survey of analysts that follow Cerecor.
Cerecor (NASDAQ:CERC) last announced its earnings results on Thursday, November 14th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.06. The business had revenue of $5.61 million for the quarter, compared to the consensus estimate of $5.15 million. Cerecor had a negative return on equity of 121.32% and a negative net margin of 113.66%.
CERC has been the topic of a number of analyst reports. ValuEngine lowered shares of Cerecor from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target (up from $11.00) on shares of Cerecor in a report on Monday. Finally, Maxim Group reaffirmed a “buy” rating and set a $10.00 price target on shares of Cerecor in a report on Friday, November 15th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Cerecor currently has a consensus rating of “Buy” and an average target price of $10.00.
NASDAQ CERC traded up $0.08 on Friday, reaching $3.63. The company had a trading volume of 1,288 shares, compared to its average volume of 57,243. The company has a quick ratio of 0.71, a current ratio of 0.73 and a debt-to-equity ratio of 0.78. Cerecor has a 1 year low of $2.71 and a 1 year high of $7.65. The firm has a 50-day moving average of $3.36 and a 200-day moving average of $3.97.
In other Cerecor news, major shareholder Armistice Capital Master Fund acquired 2,200,000 shares of the stock in a transaction on Friday, September 6th. The stock was purchased at an average price of $3.05 per share, for a total transaction of $6,710,000.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Armistice Capital, Llc acquired 1,000,000 shares of the stock in a transaction on Friday, September 6th. The shares were acquired at an average price of $2.95 per share, with a total value of $2,950,000.00. The disclosure for this purchase can be found here. Insiders own 64.30% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp raised its stake in shares of Cerecor by 47.4% in the second quarter. Northern Trust Corp now owns 55,971 shares of the company’s stock worth $304,000 after acquiring an additional 17,999 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Cerecor by 294.9% in the second quarter. Bank of New York Mellon Corp now owns 57,428 shares of the company’s stock valued at $312,000 after purchasing an additional 42,885 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new position in shares of Cerecor during the 2nd quarter worth approximately $288,000. State Street Corp increased its position in shares of Cerecor by 20.6% during the 3rd quarter. State Street Corp now owns 342,223 shares of the company’s stock worth $1,126,000 after purchasing an additional 58,538 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Cerecor by 612.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 72,670 shares of the company’s stock worth $355,000 after purchasing an additional 62,473 shares in the last quarter. Institutional investors own 60.87% of the company’s stock.
Cerecor Company Profile
Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.
Featured Article: What is a growth and income fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.